This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
cannabis: Archive
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
biotechs cannabis medical pharmaceuticals
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
cannabis healthcare marijuana marijuana-stocks medical
IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
Innovative Industrial's Q4 performance is likely to have been affected by a decline in contractual rent and property management fees and elevated expenses.
cannabis finance marijuana reit
Is IIPR Stock a Buy, Hold or Sell After Its 49% Plunge in 3 Months?
by Moumita C. Chattopadhyay
With a volatile cannabis market and tenant risks, is IIPR's high yield sustainable, or will challenges overshadow its growth?
cannabis finance marijuana marijuana-stocks reit
GrowGeneration Earnings Miss Estimates in Q3, Revenues Dip Y/Y
by Zacks Equity Research
GRWG expects revenues between $190 million and $195 million for 2024.
basic-materials cannabis earnings
Pre-Markets Soar after Trump Wins U.S. Presidential Election
by Zacks Equity Research
Pre-Markets Soar after Trump Wins U.S. Presidential Election
auto-tires-trucks biotechs bitcoin blockchain cannabis cryptocurrency etfs semiconductor
Factors to Impact Innovative Industrial's (IIPR) Q2 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q2 performance, though high expenses might have played a spoilsport.
cannabis finance reit
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
cannabis medical medical-devices
4 Agriculture - Products Stocks to Watch in a Thriving Industry
by Madhurima Das
The Agriculture - Products industry is set to gain from solid demand. Stocks like WestFraser (WFG), CalMaine Foods (CALM), Andersons (ANDE) and Hydrofarm (HYFM) are poised to ride on this positive trend.
agriculture basic-materials cannabis